Company intelligence
ChemPartner
ChemPartner is a global, full-service drug discovery, development, and manufacturing CRO/CDMO.
About ChemPartner
ChemPartner is a global contract research organization (CRO) trusted by pharmaceutical and biotech companies for seamless, scalable support from discovery through IND. With scientific expertise spanning discovery biology, pharmacology, DMPK, bioanalysis, and chemistry, we provide fully integrated solutions tailored to the needs of innovative drug developers worldwide. We support projects across all major therapeutic modalities, including small molecules, biologics, antibody-drug conjugates (ADCs), and cell and gene therapies. Our scientists are deeply collaborative—working as an extension of your team to design and execute studies that deliver meaningful, decision-driving data. Whether you are a startup advancing your first candidate or an established company looking to scale, ChemPartner offers the scientific partnership, flexibility, and operational excellence needed to accelerate your path to the clinic. Capabilities Include: Discovery Biology & Mechanism-of-Action Studies In Vitro & In Vivo Pharmacology DMPK & Bioanalysis Medicinal & Synthetic Chemistry Biologics Discovery (including B-cell cloning, hybridoma, and phage display) Oncology, Immunology, and Infectious Disease Models IND-Enabling Support With a strong track record of scientific innovation and global delivery, ChemPartner is committed to helping our partners solve complex R&D challenges.
Verified activity
Signals from ChemPartner
10 published signals
Presence & Recognition
ChemPartner scientist Phil Clarke presented a poster titled Antibody-Oligonucleotide Conjugates: From Stochastic Purification to Site-Specific Conjugation at EFMC Medicinal Chemistry 2026.
Reported by ChemPartner
Presence & Recognition
ChemPartner finished its first day in Basel at EFMC Medicinal Chemistry 2026.
Reported by ChemPartner
Presence & Recognition
ChemPartner attended the EFMC Medicinal Chemistry 2026 conference in Basel.
Reported by ChemPartner
Presence & Recognition
ChemPartner participated in the EFMC Medicinal Chemistry 2026 conference in Basel, showcasing talks and conversations at the booth.
Reported by Philip Clarke
Presence & Recognition
ChemPartner is attending Nordic Life Science Days 2026 in Stockholm from September 8-9, 2026, where it will showcase integrated discovery-to-CMC support.
Reported by ChemPartner
Presence & Recognition
ChemPartner hosted the ChemPartner Discovery Day at the Boston Center of Excellence on September 24 to celebrate its one-year anniversary and bring the Boston life sciences community together.
Reported by ChemPartner
Presence & Recognition
ChemPartner is presenting at EFMC Medicinal Chemistry 2026 at the Poster Session 1 on Monday, September 7, 18:00–19:30 at Booth #6.
Reported by ChemPartner
Research & Knowledge
ChemPartner Insights published Issue 02 of the ChemPartner Insights series, which works through HDM-induced asthma in BALB/c mice end to end, including study design, Penh, BALF IL-4 and IL-13, serum IgE, histopathology, and sets the OVA mouse and rat models alongside it.
Reported by ChemPartner
Presence & Recognition
ChemPartner is exhibiting at EFMC Medicinal Chemistry 2026 at the EFMC International Symposium on Medicinal Chemistry in Basel.
Reported by ChemPartner
Products & Services
ChemPartner built the Biology Database as an integrated translational research resource combining a comprehensive tumor model portfolio with over 100 million experimental data points and analytical tools to support decision-making from target validation through IND-enabling studies.
Reported by ChemPartner